AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. secured $37 million in Series A financing led by InnoPinnacle Fund to advance AHB-137 clinical development for HBV cure.
Amount Raised
$37 Million
Round Type
Series A
Investors
Description
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. announced the completion of a $37 million Series A financing round to further support the clinical development of AHB-137, their lead product candidate, and advance their proprietary Med-Oligo™ technology platform and product pipelines.
Quick answer
AusperBio raised $37 Million in a Series A round, dated July 15, 2024. Investors: Genesis Capital, Hankang Capital, Qiming Venture Partners, Yuanbio Venture Capital and Inno Pinnacle Fund.
- How much did AusperBio raise?
- AusperBio raised $37 Million in a Series A round on July 15, 2024.
- Who invested in AusperBio?
- Genesis Capital, Hankang Capital, Qiming Venture Partners, Yuanbio Venture Capital and Inno Pinnacle Fund are named as investors in this round.
- What does AusperBio do?
- AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus..
- Where is AusperBio based and how big is it?
- Fundz records about 100 employees.
- Who are the decision-makers at AusperBio?
- Fundz holds 4 contacts at AusperBio, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as AusperBio that raised within 45 days of this round, from Fundz verified event records.
- Retension Pharmaceuticals raised $10M (Series A) on August 21, 2024.
- Pathalys Pharma raised $105M (Series B) on August 21, 2024.
- Lipella Pharmaceuticals raised $120K on July 31, 2024.
- Ensho Therapeutics raised $400K on July 19, 2024.
- Renalys Pharma raised $38M (Series A) on July 17, 2024.
- SciRhom GmbH raised $70M (Series A) on July 9, 2024.
Who to call at AusperBio, and when
A new round usually means AusperBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AusperBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AusperBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AusperBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.